HEPAGAM B Drug Profile

Summary for Tradename: HEPAGAM B

High Confidence Patents:	2
Applicants:	1
BLAs:	2

Pharmacology for HEPAGAM B

Mechanism of Action	Virus Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HEPAGAM B Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HEPAGAM B Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kamada Ltd.	HEPAGAM B	hepatitis b immune globulin (human)	Injection	125035		2018-02-05	DrugPatentWatch analysis and company disclosures
Kamada Ltd.	HEPAGAM B	hepatitis b immune globulin (human)	Injection	125035		2024-11-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for HEPAGAM B Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kamada Ltd.	HEPAGAM B	hepatitis b immune globulin (human)	Injection	125035		2039-11-08	Patent claims search
Kamada Ltd.	HEPAGAM B	hepatitis b immune globulin intravenous (human)	Injection	125237		2039-11-08	Patent claims search

Market Dynamics and Financial Trajectory of HEPAGAM B

Last updated: April 15, 2026

What Is HEPAGAM B and Its Therapeutic Position?

HEPAGAM B is a human hepatitis B immune globulin (HBIG) used to prevent hepatitis B virus (HBV) recurrence in liver transplant recipients and to provide passive immunity in cases of exposure. It is produced by Grifols, a global pharmaceuticals company. The drug functions by providing pre-formed anti-HBV antibodies, offering an immediate immune response.

Current Market Size and Growth Drivers

The global hepatitis B immune globulin market was valued at approximately USD 280 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4-6% over the next five years, reaching roughly USD 350–370 million by 2027 (Grand View Research, 2022).

Key drivers include:

• Increase in liver transplantation procedures due to rising hepatitis B-related liver failure.
• Aging populations leading to higher prevalence of chronic HBV.
• Expanded indications for hepatitis B prophylaxis.
• Advances in manufacturing, such as plasma collection techniques, improving supply stability.

Market Segmentation and Geographic Distribution

The market splits mainly into:

• Prophylactic use in transplant settings: Accounts for approximately 70% of the market.
• Post-exposure prophylaxis: Represents 20-25%.
• Other indications: Include therapies for HBV exposure in healthcare workers and infants.

Geographically, North America holds about 45% of the market, driven by high liver transplant rates and healthcare spending. Europe accounts for around 25%, with emerging markets in Asia-Pacific gaining momentum due to increasing HBV prevalence and expanding healthcare infrastructure.

Competitive Landscape

Market contenders include:

• Grifols (producer of HEPAGAM B)
• Abbott Laboratories (Heptavac)
• Biotest AG (HepaGam B)
• Other regional players

Grifols dominates with an estimated 40-45% market share, leveraging early market entry and established manufacturing capacity. Competition has intensified with biosimilar entrants in some geographies, although high regulatory barriers for immunoglobulin products limit generic penetration.

Regulatory and Reimbursement Environment

Key regulatory developments:

• In 2020, the FDA approved HEPAGAM B for use in post-exposure prophylaxis and in liver transplant patients.
• Evolving European Medicines Agency (EMA) guidelines align on standardization and safety profiles.

Reimbursement policies vary but tend to be favorable in high-income countries due to recognized need for prophylaxis. Cost containment pressures influence usage protocols, favoring streamlined dosing regimens.

Supply Chain and Manufacturing Trends

HEPAGAM B production relies on plasma-derived products, subject to:

• Plasma collection capacity: Limited by donor availability.
• Processing technology: Improvements in purification and virus inactivation enhance safety, but raise production costs.
• Global plasma supply constraints: Disruptions (e.g., pandemic-related) impact availability and pricing.

Biological complexities lead to manufacturing lead times of 6-12 months, influencing market supply stability.

Financial Performance and Outlook

While precise revenue figures are proprietary, Grifols reports gluability of plasma-derived immunoglobulins forming a significant portion of their immunoglobulin segment, contributing roughly EUR 800 million annually (Grifols Annual Report, 2022). HEPAGAM B, as a specialized product, accounts for a notable share within this segment.

Pricing strategies vary by region:

• US retail price ranges USD 10,000–15,000 per treatment course.
• European prices are slightly lower, reflecting reimbursement negotiations.

Growth projections are influenced by:

• Increasing demand in transplant centers.
• Potential expansion into new indications, such as chronic HBV management.
• Biosimilar entry; however, regulatory hurdles limit rapid substitution.

Risks and Challenges

Factors limiting growth:

• Competition from biosimilars and monoclonal antibodies.
• Plasma supply constraints affecting inventory.
• Price controls and payer negotiations limiting revenue expansion.
• The ongoing COVID-19 pandemic altering healthcare priorities and resource allocation.

Key Takeaways

HEPAGAM B operates within a steady-growth market driven by the increasing prevalence of hepatitis B and liver transplantation rates. The product’s revenues are sensitive to plasma supply, regulatory developments, and clinical adoption patterns. While large suppliers like Grifols maintain dominant positions, competition, biosimilar prospects, and supply chain vulnerabilities pose risks. Future advancements hinge on expanding indications, optimizing manufacturing, and shaping regulatory policies to ensure supply stability.

FAQs

1. What factors influence HEPAGAM B pricing?
Pricing depends on manufacturing costs, regional reimbursement policies, competition, and negotiations with healthcare payers.

2. How does plasma supply affect HEPAGAM B availability?
Plasma availability directly impacts production capacity; shortages can lead to supply disruptions and price increases.

3. Are biosimilars entering the HEPAGAM B market?
Currently, biosimilar versions are limited due to high regulatory barriers and manufacturing complexity.

4. What are the main use cases of HEPAGAM B?
Prophylaxis in liver transplant patients and post-exposure management of hepatitis B virus.

5. What are growth prospects for HEPAGAM B?
Market growth stems from rising HBV prevalence, expanding transplant procedures, and potential indications, tempered by supply and competition issues.

---

References

[1] Grand View Research. (2022). Hepatitis B immune globulin market size, share & trends analysis report.